Article ; Online: Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme.
2024 Volume 14, Issue 1, Page(s) 66
Abstract: CAR T-cell therapy has transformed relapsed/refractory (r/r) B-cell precursor ...
| Abstract | CAR T-cell therapy has transformed relapsed/refractory (r/r) B-cell precursor acute lymphoblastic leukaemia (B-ALL) management and outcomes, but following CAR T infusion, interventions are often needed. In a UK multicentre study, we retrospectively evaluated tisagenlecleucel outcomes in all eligible patients, analysing overall survival (OS) and event-free survival (EFS) with standard and stringent definitions, the latter including measurable residual disease (MRD) emergence and further anti-leukaemic therapy. Both intention-to-treat and infused cohorts were considered. We collected data on feasibility of delivery, manufacture, toxicity, cause of therapy failure and followed patients until death from any cause. Of 142 eligible patients, 125 received tisagenlecleucel, 115/125 (92%) achieved complete remission (CR/CRi). Severe cytokine release syndrome and neurotoxicity occurred in 16/123 (13%) and 10/123 (8.1%), procedural mortality was 3/126 (2.4%). The 2-year intent to treat OS and EFS were 65.2% (95%CI 57.2-74.2%) and 46.5% (95%CI 37.6-57.6%), 2-year intent to treat stringent EFS was 35.6% (95%CI 28.1-44.9%). Median OS was not reached. Sixty-two responding patients experienced CAR T failure by the stringent event definition. Post failure, 1-year OS and standard EFS were 61.2% (95%CI 49.3-75.8) and 55.3% (95%CI 43.6-70.2). Investigation of CAR T-cell therapy for B-ALL delivered on a country-wide basis, including following patients beyond therapy failure, provides clinicians with robust outcome measures. Previously, outcomes post CAR T-cell therapy failure were under-reported. Our data show that patients can be successfully salvaged in this context with good short-term survival. |
|---|---|
| MeSH term(s) | Child ; Humans ; Adolescent ; Receptors, Chimeric Antigen ; Intention to Treat Analysis ; Retrospective Studies ; Receptors, Antigen, T-Cell ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy ; Immunotherapy, Adoptive/adverse effects ; Antigens, CD19 |
| Chemical Substances | tisagenlecleucel (Q6C9WHR03O) ; Receptors, Chimeric Antigen ; Receptors, Antigen, T-Cell ; Antigens, CD19 |
| Language | English |
| Publishing date | 2024-04-15 |
| Publishing country | United States |
| Document type | Multicenter Study ; Journal Article |
| ZDB-ID | 2600560-8 |
| ISSN | 2044-5385 ; 2044-5385 |
| ISSN (online) | 2044-5385 |
| ISSN | 2044-5385 |
| DOI | 10.1038/s41408-024-01038-2 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.